Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet Therapy Study Versus the National Cardiovascular Data Registry
暂无分享,去创建一个
S. Normand | W. Weaver | J. Rumsfeld | L. Mauri | R. Brindis | D. Holmes | R. Yeh | M. Roe | D. Kereiakes | Priscilla Driscoll-Shempp | Sunghee Kim | M. Czarny | John S. Rumsfeld
[1] Brian J. McCourt,et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. , 2014, JACC. Cardiovascular interventions.
[2] J. McMurray,et al. Large streamlined trials in cardiovascular disease. , 2014, European heart journal.
[3] Paul Heidenreich,et al. Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. , 2013, Journal of the American College of Cardiology.
[4] David Erlinge,et al. Thrombus aspiration during ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.
[5] Ralph B D'Agostino,et al. The randomized registry trial--the next disruptive technology in clinical research? , 2013, The New England journal of medicine.
[6] Mitchell W Krucoff,et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). , 2013, American heart journal.
[7] D. Kent,et al. Evidence of Systematic Duplication by New Percutaneous Coronary Intervention Programs , 2013, Circulation. Cardiovascular quality and outcomes.
[8] Mike Lauer. Commentary: How the debate about comparative effectiveness research should impact the future of clinical trials , 2012, Statistics in medicine.
[9] S. Normand,et al. Comparative effectiveness research: does one size fit all? , 2012, Statistics in medicine.
[10] J. Messenger,et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.
[11] K. Winters,et al. Rationale and design of the TAXUS Libertē Post-Approval Study: examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice. , 2012, American heart journal.
[12] P. Serruys,et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. , 2011, European heart journal.
[13] M. Pencina,et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent , 2010, American heart journal.
[14] Bryan R Luce,et al. Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change , 2009, Annals of Internal Medicine.
[15] Peter C. Austin,et al. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..
[16] M. Hamon,et al. Coronary Stents and Chronic Anticoagulation , 2009, Circulation.
[17] G. Guyatt,et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[18] R. Redberg,et al. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. , 2008, Archives of internal medicine.
[19] G. Guyatt,et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[20] F. Van de Werf,et al. External validity of clinical trials in acute myocardial infarction. , 2007, Archives of internal medicine.
[21] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.
[22] Jack V Tu,et al. Impracticability of informed consent in the Registry of the Canadian Stroke Network. , 2004, The New England journal of medicine.
[23] D. Stryer,et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.
[24] Harlan M Krumholz,et al. Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.
[25] K. Alexander,et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. , 2001, JAMA.
[26] P S Douglas,et al. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. , 2000, The New England journal of medicine.
[27] J. Avorn,et al. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.